400 related articles for article (PubMed ID: 23621801)
1. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.
Camilleri M
Expert Opin Pharmacother; 2013 Jun; 14(9):1151-60. PubMed ID: 23621801
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Nee J; Zakari M; Lembo AJ
Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
[TBL] [Abstract][Full Text] [Related]
3. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Bleser S
Curr Med Res Opin; 2011 Mar; 27(3):503-12. PubMed ID: 21208139
[TBL] [Abstract][Full Text] [Related]
4. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
6. Advancements in drug development for diarrhea-predominant irritable bowel syndrome.
Dothel G; Barbaro MR; Raschi E; Barbara G; De Ponti F
Expert Opin Investig Drugs; 2018 Mar; 27(3):251-263. PubMed ID: 29451407
[TBL] [Abstract][Full Text] [Related]
7. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
8. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
9. Drug discovery approaches to irritable bowel syndrome.
Hornby PJ
Expert Opin Drug Discov; 2015; 10(8):809-24. PubMed ID: 26193876
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome.
Munjal A; Dedania B; Cash BD
Expert Opin Pharmacother; 2020 Jan; 21(1):63-71. PubMed ID: 31738621
[No Abstract] [Full Text] [Related]
11. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
12. Peripherally acting therapies for the treatment of irritable bowel syndrome.
Saad RJ
Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
[TBL] [Abstract][Full Text] [Related]
13. Emerging drug for diarrhea predominant irritable bowel syndrome.
Deiana S; Gabbani T; Bagnoli S; Annese V
Expert Opin Emerg Drugs; 2015 Jun; 20(2):247-61. PubMed ID: 25732091
[TBL] [Abstract][Full Text] [Related]
14. Asimadoline in the treatment of irritable bowel syndrome.
Mangel AW; Williams VS
Expert Opin Investig Drugs; 2010 Oct; 19(10):1257-64. PubMed ID: 20809870
[TBL] [Abstract][Full Text] [Related]
15. New and Investigational Agents for Irritable Bowel Syndrome.
Wadhwa A; Camilleri M; Grover M
Curr Gastroenterol Rep; 2015 Dec; 17(12):46. PubMed ID: 26446557
[TBL] [Abstract][Full Text] [Related]
16. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Lewis JH
Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
[TBL] [Abstract][Full Text] [Related]
17. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
Johanson JF
Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of treatment continuation with alosetron by IBS-D severity criteria.
Nicandro JP; Shin P; Chuang E
Curr Med Res Opin; 2012 Mar; 28(3):449-56. PubMed ID: 22313141
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
Schoenfeld P
Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
[TBL] [Abstract][Full Text] [Related]
20. Modern Management of Irritable Bowel Syndrome: More Than Motility.
Tack J; Vanuytsel T; Corsetti M
Dig Dis; 2016; 34(5):566-73. PubMed ID: 27331917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
